Sakakibara, Yuko
Ogino, Yumiko
Hasegawa, Miyuki
Sakaguchi, Motonobu
Narii, Nobuhiro http://orcid.org/0000-0002-0826-1358
Funding for this research was provided by:
Takeda Pharmaceutical Company
Article History
Accepted: 2 September 2024
First Online: 21 September 2024
Declarations
:
: This work was funded by Takeda Pharmaceutical Company Limited, Japan.
: All authors are full-time employees of Takeda Pharmaceutical Company Limited, a marketing authorization holder of codeine phosphate in Japan.
: Ethics approval was not applicable. Since the data used in this study are aggregate drug prescription rates and patient background, the privacy and confidentiality of the data are well-protected. Although patients can be identified via a unique identifier by JMDC Inc., the secondary database used for research purposes has de-identified data only.
: The need for informed consent and consent to publish was waived due to the retrospective nature of the study and the anonymity of the patient database.
: The data used in this study were provided on a contract basis between the sourcing vendor (JMDC Inc.) and Takeda. Upon our request, JMDC Inc. agreed to provide the data for this study without restriction. The data cannot be shared publicly due to the aforementioned contracts of both companies.
: The code used for this study are available from the corresponding author upon reasonable request.
: Y.S. and Y.O. contributed to conceptualization, formal analysis, methodology, writing—original draft, and equally contributed to this work. M.H. contributed to conceptualization, validation, methodology, and writing—review and editing. M.S. contributed to conceptualization, funding acquisition, supervision, resource, and writing—review and editing. N.N. contributed to conceptualization, formal analysis, methodology, project administration, and writing—original draft. All authors read and approved the final version.